SCHEMBL660713

SCHEMBL660713

[CH2]C1OCCc2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 1/20 0.44
RAB9A P51151 3/20 0.41
TSHR P16473 2/20 0.40
GAA P10253 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
RECQL P46063 1/20 0.40
RET P07949 1/20 0.39
HTR2A P28223 1/20 0.39
MAPK1 P28482 1/20 0.38
MEN1 O00255 1/20 0.38
BLM P54132 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPT P10636 1/20 0.38
HTR1A P08908 1/20 0.37
IDO1 P14902 1/20 0.37
PDPK1 O15530 1/20 0.37
ACP3 P15309 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27415175 0.82 HTR2A (0.39) LMNARAB9ARETHTR2ASMN1; SMN2
SCHEMBL30816126 0.80 ALDH1A1 (0.44) ALDH1A1KMT2ALMNARAB9ATSHR
SCHEMBL7343966 0.75 ALDH1A1 (0.44) ALDH1A1KMT2ALMNARAB9ATSHR
SCHEMBL660714 0.75 HTR2A (0.43) ALDH1A1KMT2ALMNARAB9ATSHR
SCHEMBL30388241 0.75 ALDH1A1 (0.41) ALDH1A1KMT2ALMNARAB9ATSHR
SCHEMBL23921624 0.75 HTR2A (0.43) ALDH1A1KMT2ALMNARAB9ATSHR
SCHEMBL25180650 0.75 ALDH1A1 (0.41) ALDH1A1KMT2ALMNARAB9ATSHR
SCHEMBL9810549 0.75 ALDH1A1 (0.41) ALDH1A1KMT2ALMNARAB9ATSHR
SCHEMBL8551292 0.75 RAB9A (0.48) ALDH1A1KMT2ALMNARAB9ATSHR
SCHEMBL7397055 0.75 RAB9A (0.44) ALDH1A1KMT2ALMNARAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1620399-B1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB PHARMA SA (BE) 2010-09-22 EP claimed
EP-2155751-A1 PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS AstraZeneca AB (SE) 2010-02-24 EP claimed
US-20090099195-A1 Therapeutic Compounds 570 ASTRAZENECA AB (SE) 2009-04-16 US claimed
WO-2008136756-A1 PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS ASTRAZENECA AB (SE) 2008-11-13 WO claimed
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses UCB, S.A. (BE) 2007-02-22 US claimed
US-20230277501-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2023-09-07 US disclosed
US-20230033195-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2023-02-02 US disclosed
US-20220218665-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2022-07-14 US disclosed
US-11160785-B2 Methods and compositions for improving cognitive function AGENEBIO INC. (US) 2021-11-02 US disclosed
US-20210244709-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2021-08-12 US disclosed
EP-3827820-A1 BRIVARACETAM FOR IMPROVING COGNITIVE FUNCTION The Johns Hopkins University (US) 2021-06-02 EP disclosed
EP-3260118-B1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2021-03-24 EP disclosed
US-7427616-B2 Condensed pyridines and pyrimidines with tie2 (TEK) activity ASTRAZENECA AB (SE) 2008-09-23 US disclosed
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses UCB, S.A. (BE) 2007-02-22 US disclosed
EP-1537112-B1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2006-04-19 EP disclosed
EP-1620399-A1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2006-02-01 EP disclosed
US-20050256140-A1 Condensed pyridines and pyrimidines with tie2 (tek) activity ASTRAZENECA AB (SE) 2005-11-17 US disclosed
EP-1537112-A1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY Astrazeneca AB (SE) 2005-06-08 EP disclosed
WO-2004087658-A1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2004-10-14 WO disclosed
WO-2004013141-A1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2004-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099195-A1 Therapeutic Compounds 570 OPRL1, OPRK1, OPRM1 ALDH1A1 245/4885KMT2A 3628/4885LMNA 4019/4885
US-20210244709-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2A, CHRNA2, SYNGR2 ALDH1A1 2177/4885KMT2A 140/4885LMNA 1805/4885
US-11160785-B2 Methods and compositions for improving cognitive function BACE2, BACE1, GRIN2A ALDH1A1 1226/4885KMT2A 530/4885LMNA 1020/4885
US-20220218665-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, RAB2A, VAMP8 ALDH1A1 2819/4885KMT2A 116/4885LMNA 2747/4885
US-20230277501-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2A, CHRNA2, SYNGR2 ALDH1A1 2177/4885KMT2A 140/4885LMNA 1805/4885
US-20050256140-A1 Condensed pyridines and pyrimidines with tie2 (tek) activity TIE1, TEK, KDR ALDH1A1 2177/4885KMT2A 287/4885LMNA 3041/4885
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses AANAT, TPH2, CYP1A2 ALDH1A1 308/4885KMT2A 1267/4885LMNA 1352/4885
US-20230033195-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2D, GRIN2A, SLC18A2 ALDH1A1 2755/4885KMT2A 478/4885LMNA 1152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.